References
- LiXQWeidolfLSimonssonRAnderssonTBEnantiomer/enantiomer interactions between the S- and R-isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4J Pharmacol Exp Ther2005315277778716093273
- SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte-an update of guidelinesClin Pharmacol Ther201189566267321412232
- KuehlPZhangJLinYSequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNat Genet200127438339111279519
- DalyAKSignificance of the minor cytochrome P450 3A isoformsClin Pharmacokinet2006451133116430309
- Martinez-JimenezCPJoverRDonatoMTCastellJVGomez-LechonMJTranscriptional regulation and expression of CYP3A4 in hepatocytesCurr Drug Metab20078218519417305497
- SugimotoKUnoTTateishiTEffects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMsEur J Clin Pharmacol200864658358718214455
- ShinKHAhnLYChoiMHUrinary 6β-hydroxycortisol/cortisol ratio most highly correlates with midazolam clearance under hepatic CYP3A inhibition and induction in females: a pharmacometabolomics approachAAPS J20161851254126127317471
- WangDGuoYWrightonSACookeGESadeeWIntronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugsPharmacogenomics J201111427428620386561
- ElensLBeckerMLHaufroidVNovel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam StudyPharmacogenet Genomics2011211286186621946898
- ElensLBouamarRHesselinkDAA new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmaco-kinetics in kidney transplant recipientsClin Chem201157111574158321903774
- PasseyCBirnbaumAKBrundageRCValidation of tacrolimus equation to predict troughs using genetic and clinical factorsPharmacogenomics201213101141114722909204
- LeeSJGoldsteinJAFunctionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping testsPharmacogenomics2005635737116004554
- KochIWeilRWolboldRInterindividual variability and tissue specificity in the expression of cytochrome P450 3A mRNADrug Metab Dispos200230101108111412228187
- ElensLBouamarRHesselinkDAHaufroidVvan GelderTvan SchaikRHThe new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patientsPharmacogenet Genomics201222537338022388796
- LiYZhangWGuoDZhouGZhouHXiaoZPharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypesClin Chim Acta20083911–2606718319058
- ElensLvan GelderTHesselinkDAHaufroidVvan SchaikRHCYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapyPharmacogenomics2013141476223252948
- DenisenkoNPSychevDASizovaZMUrine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patientsPharmgenomics Pers Med20171025325929033601
- ZangerUMSchwabMCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variationPharmacol Ther2013138110314123333322
- MustafinaOETuktarovaIAKarimovDDSomovaRsNasibullinTRCYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populationsGenetika2015511109119 Russian25857198
- ZastrozhinMSGrishinaEARyzhikovaKAThe influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addictionPharmgenomics Pers Med2017111529343979
- LambaJKLinYSSchuetzEGThummelKEGenetic contribution to variable human CYP3A-mediated metabolismAdv Drug Deliv Rev200254101271129412406645
- DaiDTangJRoseRIdentification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifosJ Pharmacol Exp Ther2001299382583111714865
- EiseltRDomanskiTLZibatAIdentification and functional characterization of eight CYP3A4 protein variantsPharmacogenetics200111544745811470997
- OzdemirVKalowWTangBKEvaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration methodPharmacogenetics200010537338810898107